RE:RE:PR issued by Thpalinc2000 wrote: https://www.prnewswire.com/news-releases/theratechnologies-partner-submits-biologics-license-application-for-hiv-monoclonal-antibody-and-long-acting-investigational-antiretroviral-ibalizumab-300451193.html
Among the news, most important is the number of Possible patients Ibalizumab will have:
As HIV multiplies in the body, the virus sometimes mutates to produce drug-resistant strains. When this occurs, HIV medicines that previously controlled a person's virus may no longer be effective, causing treatment to fail.
Approximately 20,000 to 25,000 Americans with HIV-1 are currently resistant to at least one drug in three different classes of antiretroviral therapies, and up to 12,000 of these patients experience a virological failure over a period of 48 weeks of treatment, requiring their physician to modify their treatment.